Heron Therapeutics Inc (HRTX)
2.455
-0.10
(-3.73%)
USD |
NASDAQ |
Apr 26, 16:00
2.455
0.00 (0.00%)
After-Hours: 18:20
Heron Therapeutics Research and Development Expense (Quarterly): 10.95M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.95M |
| September 30, 2023 | 13.56M |
| June 30, 2023 | 17.57M |
| March 31, 2023 | 13.82M |
| December 31, 2022 | 11.06M |
| September 30, 2022 | 25.54M |
| June 30, 2022 | 28.83M |
| March 31, 2022 | 42.07M |
| December 31, 2021 | 28.88M |
| September 30, 2021 | 28.60M |
| June 30, 2021 | 35.23M |
| March 31, 2021 | 38.12M |
| December 31, 2020 | 44.45M |
| September 30, 2020 | 49.18M |
| June 30, 2020 | 44.00M |
| March 31, 2020 | 36.89M |
| December 31, 2019 | 48.28M |
| September 30, 2019 | 34.71M |
| June 30, 2019 | 41.42M |
| March 31, 2019 | 42.97M |
| December 31, 2018 | 39.89M |
| September 30, 2018 | 30.42M |
| June 30, 2018 | 30.16M |
| March 31, 2018 | 39.56M |
| December 31, 2017 | 47.76M |
| Date | Value |
|---|---|
| September 30, 2017 | 28.84M |
| June 30, 2017 | 28.60M |
| March 31, 2017 | 33.38M |
| December 31, 2016 | 29.50M |
| September 30, 2016 | 30.24M |
| June 30, 2016 | 27.29M |
| March 31, 2016 | 16.09M |
| December 31, 2015 | 16.26M |
| September 30, 2015 | 14.24M |
| June 30, 2015 | 16.18M |
| March 31, 2015 | 14.50M |
| December 31, 2014 | 14.20M |
| September 30, 2014 | 14.73M |
| June 30, 2014 | 14.28M |
| March 31, 2014 | 11.63M |
| December 31, 2013 | 8.354M |
| September 30, 2013 | 6.216M |
| June 30, 2013 | 10.81M |
| March 31, 2013 | 7.14M |
| December 31, 2012 | 5.152M |
| September 30, 2012 | 3.626M |
| June 30, 2012 | 3.067M |
| March 31, 2012 | 3.329M |
| December 31, 2011 | 2.855M |
| September 30, 2011 | 2.929M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.95M
Minimum
Dec 2023
49.18M
Maximum
Sep 2020
31.22M
Average
34.71M
Median
Sep 2019
Research and Development Expense (Quarterly) Benchmarks
| United Therapeutics Corp | 151.40M |
| Esperion Therapeutics Inc | 17.74M |
| Aldeyra Therapeutics Inc | 4.298M |
| Ocular Therapeutix Inc | 16.20M |
| Clearside Biomedical Inc | 6.313M |